Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Moleculin Biotech ( (MBRX) ) has provided an announcement.
On July 17, 2025, Moleculin Biotech announced the appointment of Adriano Treve as a Strategic Advisor for partnerships. Treve, with over 40 years of experience at Roche, is expected to enhance Moleculin’s strategic positioning as the company approaches key milestones in its clinical trials, particularly the Phase 2B/3 MIRACLE trial for Annamycin. His expertise in global healthcare markets and strategic partnerships is anticipated to significantly expand opportunities for Moleculin, potentially impacting the global oncology drug market and creating value for shareholders.
The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viral infections. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases, aiming to overcome multidrug resistance and cardiotoxicity issues associated with current treatments.
Average Trading Volume: 4,602,991
Technical Sentiment Signal: Sell
Current Market Cap: $18.99M
For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.